Mink Therapeutics, Inc. (INKT)

$0.9301

-0.01

(-1.13%)

Market is closed - opens 7 PM, 08 May 2024

Performance

  • $0.92
    $0.97
    $0.93
    downward going graph

    0.7%

    Downside

    Day's Volatility :4.82%

    Upside

    4.15%

    downward going graph
  • $0.75
    $3.34
    $0.93
    downward going graph

    19.35%

    Downside

    52 Weeks Volatility :77.54%

    Upside

    72.16%

    downward going graph

Returns

PeriodMink Therapeutics, Inc.
3 Months
8.14%
6 Months
-21.84%
1 Year
-48.9%
3 Years
-92.25%

Highlights

Market Capitalization
30.2M
Book Value
- $0.52
Earnings Per Share (EPS)
-0.65
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-110.1%
Return On Equity TTM
-1238.98%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-22.7M
Diluted Eps TTM
-0.65
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.56
EPS Estimate Next Year
-0.6
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Mink Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 760.12%

Current $0.93
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Mink Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mink Therapeutics, Inc.
Mink Therapeutics, Inc.
-29.54%
-21.84%
-48.9%
-92.25%
-92.25%
Moderna, Inc.
Moderna, Inc.
15.21%
69.71%
-8.11%
-23.64%
414.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.36%
17.89%
28.96%
93.09%
194.82%
Novo Nordisk A/s
Novo Nordisk A/s
-0.13%
25.09%
51.14%
233.74%
425.88%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.49%
8.83%
19.22%
92.69%
142.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mink Therapeutics, Inc.
Mink Therapeutics, Inc.
NA
NA
NA
-0.56
-12.39
-1.1
NA
-0.52
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mink Therapeutics, Inc.
Mink Therapeutics, Inc.
Buy
$30.2M
-92.25%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
414.32%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
194.82%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
425.88%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
142.73%
28.81
36.68%

Institutional Holdings

  • Vanguard Group Inc

    0.67%
  • Longbow Finance SA

    0.48%
  • Renaissance Technologies Corp

    0.27%
  • Geode Capital Management, LLC

    0.26%
  • BlackRock Inc

    0.22%
  • CapTrust Financial Advisors

    0.16%

Corporate Announcements

  • Mink Therapeutics, Inc. Earnings

    Mink Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Mink Therapeutics, Inc.
Employees
31
CEO
Dr. Garo H. Armen Ph.D.
Industry
Services

FAQs